Post categorized under: Health Diagnostics
All too often in the conversation COVID-19 testing, two factors are lost: Pragmatism and Cost. Our Microarray platform can deliver highly effective Pooled Surveillance at a dramatically lower cost than individual testing and we are the proven alternative in Variant Identification—results in a fraction of the time and cost of NGS. The world is coming around to our way of thinking.
- AY.4.2, A Delta Covid-19 Coronavirus Subvariant, Has Spread To 42 Countries
This AY.4.2 takes the Delta variant and raises it three additional mutations, including two that affect the important spike proteins that studs the surface of the virus. The big question, of course, is whether these mutations make the virus more transmissible and potentially more lethal as well.
- Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity
A recent study shows that a new A.30 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can evade vaccine-induced antibodies and might spread outside the lungs extraordinarily well. This finding holds important implications for our public health response.
- Escape Variants and how vaccine producers are struggling to prep for them
It is not clear how public health authorities will determine that there is an escape variant and, therefore, that a novel vaccine is required. But once there is, it can be difficult to find unvaccinated volunteers in the first place. Finding unvaccinated individuals willing to submit to an experimental trial may be even harder. Recruiting placebo groups could present an ethical dilemma, as well.